Related Experiment Video
Updated: Aug 15, 2026

Experimental Human Pneumococcal Carriage
Published on: February 15, 2013
[Antipneumococcal vaccine: up date and prospective]
1Divisione di Pediatria e Neonatologia, Azienda Ospedaliera Materno Infantile G. Salesi, Ancona. caramiagm@libero.it
Abstract:
The authors, after a brief survey of the historical evolution of the antipneumococcal vaccines, concentrate on the most recent acquisitions concerning epidemiologic infections of pneumococcus in Italy and abroad. What emerged is the importance of prevention through an efficacious vaccination of the invasive forms particularly frequent in infants. Among there, and above all, meningitis; when not fatal, is very often the cause of serious illness. For this motive with the availability today of efficacious conjugated vaccine in infancy, a period with more frequent and invasive forms, it was first proposed to offer an antipneumococcal vaccination to children under 5 years of age that present particular clinical pathological conditions and later reconsidered the opportunity to extend the vaccination. Discussed and underlined are the differences between antipneumococcal vaccines available today, the importance of vaccinal coverage with conjugated vaccine from the first months of birth, and the fact that on extended vaccination campaign with such a vaccine can reduce the state of nasopharyngeal carriage of serotypes contained in the vaccine ever though penicillin resistant with an increase, however, of the state of carriage for serotypes not contained in the vaccine giving place to a phenomenon some call ''replacement'' of pathogens with non-pathogen germs. An ulterior benefit over the pneumococcal pathology is represented by the significative effect of ''herd immunity'' on subjects not vaccinated, factor that underscores the opportunity to extend the vaccination as much as possible. The importance of a precocious and rapid diagnosis with the tests available today and the necessity to vaccinate ever subjects that have overcome a serious pneumococcal infection in order to protect the subject from other types of pneumococcal particularly aggressive. Even though the vaccines actually available do not represent a final solution in the prevention of pneumococcus disease and the struggle against such pathology is destined to continue, the success obtained merits a certain satisfaction.
More Related Videos
13:47Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens
Published on: May 19, 2020
11:32Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
Published on: February 23, 2014
Related Concept Videos
Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Respiratory Syncytial Virus Disease
Pneumonia I: Introduction
Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pneumonia III: Complications and Assessment